Opioid Crisis to Increase in Upcoming Years

Researchers at the Massachusetts General Hospital Institute for Technology Assessments (MGH-ITA) estimate that restricting access to prescription opioids will have minimal effects on the opioid overdose epidemic, which they project to increase in the future. In a study published in JAMA Open Network, the authors predict that the changing nature of the epidemic, driven by the illegal use of opioids such as heroin and fentanyl, has reduced the potential impact of programs that target prescription opioids.
According to corresponding author Jagpreet Chhatwal, PhD, of MGH-ITA, the opioid epidemic began in the 1990s due an upsurge in opioid prescriptions. In 2010, he stated, the crisis included a rise in deaths from both prescription opioid overdoses and in overdose deaths due to heroin.
"In the past 5 years, deaths have accelerated with the introduction of the powerful synthetic opioid fentanyl into the opioid supply, leading to a continuing increase in overdose deaths at time when the supply of prescription opioids is decreasing,” Chhatwal said in a press release.
According to the press release, Chhatwal's team used data from sources such as the National Survey on Drug Use and Health and the CDC to develop the Opioid Policy Model, reflecting the trajectory of the opioid epidemic in the United States from 2002 to 2015. That model was then used to project probable outcomes from 2016 to 2025.
The researchers’ model followed a status quo scenario, in which the future misuse of prescription opioids would not decrease over time. According to the study, the model projects that the annual number of opioid overdose deaths will increase from 33,100 in 2015 to 81,700 in 2025, an increase of 147%. The model also predicts that during those years, a total of approximately 700,000 people will die from an opioid overdose, 80% from illicit drugs such as heroin and fentanyl. By 2025, half of all new opioid users are predicted to begin with illicit rather than prescription drugs. In all scenarios tested, interventions directed towards reducing misuse of prescription opioids were projected to decrease overdose deaths by only 3% to 5%.
"This study demonstrates that initiatives focused on the prescription opioid supply are insufficient to bend the curve of opioid overdose deaths in the short and medium term,” co-author Marc Larochelle, MD, MPH, of the Grayken Center for Addiction at Boston Medical Center, an assistant professor of Medicine at Boston University School of Medicine, said in the release. “We need policy, public health and health care delivery efforts to amplify harm reduction efforts and access to evidence-based treatment."
Chhatwal adds, "If we rely solely on controlling the supply of prescription opioids, we will fail miserably at stemming the opioid overdose crisis. Illicit opioids now cause the majority of overdose deaths, and such deaths are predicted to increase by 260%¾from 19,000 to 68,000¾between 2015 and 2025. A multipronged approach, including strategies to identify those with opioid use disorder, improved access to medications like methadone and buprenorphine, and expansion of harm reduction services such as the overdose-reversal drug naloxone, will be required to reduce the rate of opioid overdose deaths." 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
There are currently firms working to use artificial intelligence in hopes that it could contribute to minimizing the impact of the opioid epidemic.
An implantable form of naltrexone was more effective in improving HIV outcomes in patients compared with oral naltrexone.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.